Europe Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)- Industry Trends and Forecast to 2030.
Europe Nasal Spray Market Analysis and Insights
Allergic rhinitis is a major health problem that causes problems in more than 500 million people in the world. It has symptoms such as nasal congestion, snoring, postnasal drip, and cough, reduction in the sense of smell, headache, and others for months or years in almost half of the patients on earth. These symptoms can also affect the quality of life of patients.
A nasal spray is a device widely used as a system in nasal drug delivery to treat major allergy problems such as nasal congestion, infections, itchy or watery eyes, runny nose, chest congestion, cough, wheezing, labored breathing, shallow breathing, and others. Some other diseases which also include nasal polyps, inflammatory bowel disease, kidney-related problems, and others. Administration of medicines or drugs by the nose in dosage form with the help of spray is a non-invasive technique that provides rapid action of a drug in the body of patients. A nasal spray is one of the most cost-effective, does not require invasion, is easy to use and self-administered, and has high patient compliance. Therefore nasal drug delivery is one of the popular routes of drug administration in recent times and has a strong growth opportunity.
Nasal sprays are available in the market as over-the-counter (OTC) or prescription drugs for the treatment of nasal diseases such as nasal allergies, blocked or stuffy nose, chronic sinus, allergic rhinitis, and other problems associated with the nose. These sprays are available in the market as a pump or as canisters.
Data Bridge Market Research analyzes that the Europe nasal spray market is expected to reach a value of USD 9,855.26 million by 2030, at a CAGR of 6.5% during the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in Million, Volumes in Units, and Pricing in USD |
|
Segments Covered |
产品类型（减充血鼻喷雾剂、类固醇鼻喷雾剂、盐水溶液/盐水鼻喷雾剂等）、容器设计（泵瓶和加压罐）、剂型（多剂量、单位/单剂量和双剂量）、治疗类别（抗组胺药、鼻用类固醇、肥大细胞抑制剂和抗胆碱能药）、应用（鼻塞、过敏性和非过敏性鼻炎、中枢神经系统疾病、疫苗接种等）、处方/可用性（非处方药和处方药）、最终用户（家庭护理环境、医院、诊所和社区医疗保健） |
|
覆盖国家 |
德国、英国、法国、意大利、西班牙、瑞士、荷兰、比利时、俄罗斯、土耳其和欧洲其他地区 |
|
涵盖的市场参与者 |
EMERGENT、Cipla Inc.、Sandoz International GmbH（诺华旗下子公司）、Aytu Health（Aytu BioPharma, Inc. 子公司）、Bayer AG、GlaxoSmithKline plc.、Assertio Therapeutics, Inc.、Aurena Laboratories.、J Pharmaceuticals、St. Renatus.、Ultratech India Limited、Catalent, Inc.、Teva Pharmaceuticals USA, Inc.（Teva Pharmaceutical Industries Ltd 子公司）、Pfizer Inc.、Viatris Inc.、LEEFORD HEALTHCARE LTD 和 Aishwarya Group 等 |
市场定义
鼻喷雾剂是一种通过鼻腔将药物输送到鼻腔的装置，用于治疗过敏症和其他与脑炎、糖尿病、牙齿问题和中枢神经系统相关的问题。过敏症是人体免疫系统对外来物质产生异常反应的一种病症。鼻喷雾剂药物产品由溶液或赋形剂悬浮液形式的治疗活性成分或药物物质组成。
市场上有不同类型的鼻腔喷雾剂，例如减充血鼻腔喷雾剂、盐水鼻腔喷雾剂和类固醇鼻腔喷雾剂。减充血剂是含有药物的装置，用于治疗鼻塞，并能短期缓解鼻塞。减充血鼻腔喷雾剂含有药物，可打开鼻腔气道并帮助呼吸。
在寒冷干燥的冬季，使用盐水鼻腔喷雾剂可避免鼻塞问题。这些设备用于治疗鼻窦炎、鼻结痂和鼻腔稀薄的液体分泌物，这些分泌物是由于细菌感染而形成的，会导致鼻腔区域干燥。该设备有助于清洁鼻腔通道和因寒冷而存在于该区域的粘液。
欧洲鼻腔喷雾剂市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
司机
- 感染和过敏病例增加
过敏是一种使免疫系统变弱的疾病，免疫系统对外来物质产生异常反应。过敏有多种形式，例如过敏性鼻炎(AR)，这种疾病影响了美国近 4000 万至 5000 万人。有些过敏可能会干扰日常活动和生活质量。
由于人口增加，城市化和工业化进程大大加快，导致过敏原增加。这种过敏原是许多人过敏或感染疾病的罪魁祸首。
因此，AR 等过敏性疾病患病率的上升导致对鼻腔喷雾剂的需求增加，预计这将在未来几年推动市场增长。
克制
- 使用鼻腔喷雾剂的不良反应
许多人选择使用鼻腔喷雾剂来缓解流鼻涕和鼻塞，但长期使用鼻腔喷雾剂会引起多种副作用。类固醇鼻腔喷雾剂也称为皮质类固醇鼻腔喷雾剂，是一种喷入鼻腔的消炎药。它们可用于治疗多种疾病，包括花粉症、鼻窦炎、非过敏性鼻炎和鼻息肉。一些类固醇鼻腔喷雾剂可在药店和商店购买，而其他一些则只能凭处方购买。
长期使用鼻腔喷雾剂会导致鼻子出血，甚至头痛。有些人可能会出现其他副作用，例如成瘾甚至鼻塞。
如果长期服用大剂量，也有可能出现类固醇片剂的一些副作用，例如食欲增加，情绪变化和睡眠困难。
因此，预计鼻腔喷雾剂的不良影响将抑制市场的增长。
机会
- 扩大鼻腔喷雾剂的治疗应用
鼻内给药为局部和全身输送各种治疗剂提供了多种有用的选择，可用于治疗诸如过敏、呼吸系统疾病等许多问题。
鼻腔喷雾剂是最近开发的产品之一，例如 OptiNose 和 ViaNase，有助于将配方定位到人类鼻腔内的特定区域。
几十年来，鼻腔疗法一直是印度医学中一种著名的治疗方法。在印度医学的阿育吠陀系统中，它也被称为“NASAYA KARMA”。
鼻喷雾剂由一种或多种治疗活性成分组成，以悬浮液或溶液的形式存在于非加压分配器中。最常见的过敏症是 AR。
除了呼吸系统疾病，鼻腔喷雾剂还可用于其他治疗领域，如骨科、肾脏等，鼻腔喷雾剂在治疗和治愈此类疾病方面发挥着重要作用。未来可能会开发出其他治疗方法，帮助轻松治疗其他疾病。
挑战
- 监管障碍
许多监管机构都会对鼻腔给药进行评估，例如美国 FDA 和欧洲药品管理局 (EMA)。这些机构为任何产品在上市前提供了一套指导方针和法规。它们允许执行各种体外测试方法来确定鼻腔药物产品的特性，并且这些特性应在这些监管机构给出的可接受范围内。
鼻喷雾剂可根据鼻腔或其他疾病患者的药物剂量要求进行设计。鼻喷雾剂的某些方面可能在配方、制造、容器封闭系统、稳定性、关键步骤控制、中间体和药物产品方面存在差异。在开发鼻喷雾剂方案时，应仔细衡量这些方面。由于这些变化，产品治疗患者的能力可能会受到影响。
鼻喷雾剂制造产品的严格规则和规定对制造商获得监管机构的批准更具挑战性。喷雾特性可能受到设备设计和设备操作的影响。在鼻喷雾剂制造中，进行此类测试以获得完美的结果（即监管机构给出的可接受范围）更具挑战性。
新冠肺炎疫情对欧洲鼻腔喷雾剂市场的影响分析
COVID-19 对吸入剂和鼻喷雾剂仿制药市场产生了重大影响，因为 COVID-19 的主要症状之一是呼吸困难。疫情期间，吸入剂和鼻喷雾剂的需求增加。
例如，
- 根据 2021 年发表的一篇 MedComm 期刊文章，鼻腔喷雾剂被证实可成为一种有效的 COVID-19 治疗和疫苗选择
喷雾剂可以灭活 SARS-CoV-2 或限制其进入细胞，被认为有助于防止病毒传播到肺部或周围人群。放松封锁和恢复医疗实践预计将在后疫情时代加速市场增长。COVID-19 患者仍会出现呼吸困难等长期副作用。
最新动态
- 2023 年 1 月，欧洲医疗保健公司 Viatris Inc. (NASDAQ: VTRS) 今天宣布，已完成对 Oyster Point Pharma 和 Famy Life Sciences 的收购，以建立新的 Viatris 眼科护理部门。此次收购将有助于该公司的业务扩张。
- 2023 年 3 月，梯瓦制药工业有限公司 (Teva Pharmaceutical Industries Ltd) 的美国子公司梯瓦制药 (Teva Pharmaceuticals) 宣布在美国推出 Revlimid1（来那度胺胶囊）仿制药的附加强度版本，分别为 2.5 毫克和 20 毫克，该产品的推出将有助于该公司扩大其产品组合。
欧洲鼻腔喷雾剂市场范围
根据产品类型、容器设计、剂型、治疗类别、应用、处方/可用性和最终用户，欧洲鼻喷雾剂市场可分为七个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
产品类型
- 鼻塞缓解喷雾剂
- 类固醇鼻腔喷雾剂
- 盐水溶液/盐水鼻腔喷雾剂
- 其他的
根据产品类型，市场分为减充血鼻喷雾剂、盐水溶液/盐水鼻喷雾剂、类固醇鼻喷雾剂等。
容器设计
- 泵瓶
- 加压罐
根据容器设计，市场分为压力罐和泵瓶。
剂型
- 多剂量
- 单位/单剂量
- 双剂量
根据剂型，市场分为单位/单剂量、双剂量和多剂量。
治疗类
- 抗组胺药
- 鼻用类固醇
- 肥大细胞抑制剂
- 抗胆碱能
根据治疗类别，市场分为抗组胺药、鼻用类固醇、肥大细胞抑制剂和抗胆碱能药物。
应用
- 鼻塞
- 过敏性和非过敏性鼻炎
- 中枢神经系统疾病
- 疫苗接种
- 其他的
根据应用，市场分为鼻塞、过敏性和非过敏性鼻炎、中枢神经系统疾病、疫苗接种等。
处方/可用性
- 在柜台
- 处方
根据处方/可用性，市场分为非处方药和处方药。
最终用户
- 家庭护理环境
- 医院
- 诊所
- 社区卫生保健
根据最终用户，市场分为家庭护理环境、医院、诊所和社区医疗保健。
欧洲鼻腔喷雾剂市场区域分析/见解
欧洲鼻腔喷雾剂市场根据产品类型、容器设计、剂型、治疗类别、应用、处方/可用性和最终用户分为七个显著的部分。
本市场报告涵盖的国家包括德国、英国、法国、意大利、西班牙、瑞士、荷兰、比利时、俄罗斯、土耳其和欧洲其他国家。
2023 年，德国将主导欧洲鼻腔喷雾剂市场，因为欧洲最大的消费市场和高 GDP 市场中拥有主要市场参与者。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了欧洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
Competitive Landscape and Europe Nasal Spray Market Share Analysis
The Europe nasal spray market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the Europe nasal spray market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS: EUROPE NASAL SPRAY MARKET
5.1 INDUSTRY INSIGHTS
6 REGULATIONS: EUROPE NASAL SPRAY MARKET
6.1 REGULATORY SCENARIO IN EUROPE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY
7.2 RESTRAINTS
7.2.1 PRODUCT RECALLS
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS
7.3 OPPORTUNITIES
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 REGULATORY HURDLES
7.4.2 ADDICTION TO NASAL SPRAY
8 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 DECONGESTION NASAL SPRAY
8.3 STEROID NASAL SPRAY
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY
8.5 OTHERS
9 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN
9.1 OVERVIEW
9.2 PUMP BOTTLES
9.3 PRESSURIZED CANISTERS
10 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 MULTI DOSE
10.3 UNIT/SINGLE DOSE
10.4 BI DOSE
11 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS
11.1 OVERVIEW
11.2 ANTIHISTAMINE
11.3 NASAL STEROIDS
11.4 MAST CELL INHIBITOR
11.5 ANTICHOLINERGIC
12 EUROPE NASAL SPRAY MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 NASAL CONGESTION
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS
12.4 CENTRAL NERVOUS SYSTEM DISORDERS
12.5 VACCINATION
12.6 OTHERS
13 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY
13.1 OVERVIEW
13.2 PRESCRIBED
13.3 OVER THE COUNTER
14 EUROPE NASAL SPRAY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOME CARE SETTINGS
14.3 HOSPITALS
14.4 CLINICS
14.5 COMMUNITY HEALTH CARE
15 EUROPE NASAL SPRAY MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 U.K.
15.1.3 FRANCE
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 SWITZERLAND
15.1.7 NETHERLANDS
15.1.8 BELGIUM
15.1.9 RUSSIA
15.1.10 TURKEY
15.1.11 REST OF EUROPE
16 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GLAXOSMITHKLINE PLC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 EMERGENT
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 CATALENT, INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 AISHWARYA GROUP
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 ASSERTIO THERAPEUTICS, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENT
18.9 AURENA LABORATORIES.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.1 BAYER AG
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 COMPANY SHARE ANALYSIS
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 CIPLA INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 J PHARMACEUTICALS.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 LEEFORD HEALTHCARE LTD
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 ST. RENATUS.
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 ULTRATECH INDIA LIMITED
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 VIATRIS INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 COMPANY SHARE ANALYSIS
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
TABLE 1 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 7 EUROPE PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 10 EUROPE MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 14 EUROPE ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 25 EUROPE PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 28 EUROPE HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 33 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 35 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 36 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 37 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 39 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 40 GERMANY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 GERMANY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 42 GERMANY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 43 GERMANY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 44 GERMANY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 45 GERMANY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 46 GERMANY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 U.K. NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 U.K. NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 49 U.K. NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 50 U.K. NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 51 U.K. NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 52 U.K. NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 53 U.K. NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 54 FRANCE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 FRANCE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 56 FRANCE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 57 FRANCE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 58 FRANCE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 FRANCE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 60 FRANCE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 61 ITALY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 ITALY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 63 ITALY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 64 ITALY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 65 ITALY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 66 ITALY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 67 ITALY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 SPAIN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 SPAIN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 70 SPAIN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 71 SPAIN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 72 SPAIN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 73 SPAIN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 74 SPAIN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 75 SWITZERLAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 SWITZERLAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 77 SWITZERLAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 78 SWITZERLAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 79 SWITZERLAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 SWITZERLAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 81 SWITZERLAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 NETHERLANDS NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 NETHERLANDS NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 84 NETHERLANDS NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 85 NETHERLANDS NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 86 NETHERLANDS NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 NETHERLANDS NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 88 NETHERLANDS NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 BELGIUM NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 BELGIUM NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 91 BELGIUM NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 92 BELGIUM NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 93 BELGIUM NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 94 BELGIUM NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 95 BELGIUM NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 RUSSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 RUSSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 98 RUSSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 99 RUSSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 100 RUSSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 101 RUSSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 102 RUSSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 TURKEY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 TURKEY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)
TABLE 105 TURKEY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)
TABLE 106 TURKEY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)
TABLE 107 TURKEY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 TURKEY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)
TABLE 109 TURKEY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 110 REST OF EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 EUROPE NASAL SPRAY MARKET: SEGMENTATION
FIGURE 2 EUROPE NASAL SPRAY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE NASAL SPRAY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE NASAL SPRAY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE NASAL SPRAY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE NASAL SPRAY MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE EUROPE NASAL SPRAY MARKET IN THE FORECAST PERIOD
FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NASAL SPRAY MARKET IN 2023 AND 2030
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE NASAL SPRAY MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR EUROPE NASAL SPRAY MARKET MANUFACTURERS IN THE FORECAST PERIOD
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE NASAL SPRAY MARKET
FIGURE 16 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 EUROPE NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022
FIGURE 21 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)
FIGURE 22 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)
FIGURE 23 EUROPE NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE
FIGURE 24 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2022
FIGURE 25 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)
FIGURE 26 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)
FIGURE 27 EUROPE NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 28 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022
FIGURE 29 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)
FIGURE 30 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)
FIGURE 31 EUROPE NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE
FIGURE 32 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2022
FIGURE 33 EUROPE NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 34 EUROPE NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 35 EUROPE NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 36 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022
FIGURE 37 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)
FIGURE 38 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)
FIGURE 39 EUROPE NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE
FIGURE 40 EUROPE NASAL SPRAY MARKET: BY END USER, 2022
FIGURE 41 EUROPE NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 43 EUROPE NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE NASAL SPRAY MARKET: SNAPSHOT (2022)
FIGURE 45 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022)
FIGURE 46 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 47 EUROPE NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 48 EUROPE NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)
FIGURE 49 EUROPE NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
